<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05013632</url>
  </required_header>
  <id_info>
    <org_study_id>PR005</org_study_id>
    <nct_id>NCT05013632</nct_id>
  </id_info>
  <brief_title>COVID-19 International Drug Pregnancy Registry</brief_title>
  <acronym>COVID-PR</acronym>
  <official_title>COVID-19 International Drug Pregnancy Registry (COVID-PR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pregistry</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pregistry</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the COVID-19 International Drug Pregnancy Registry (COVID-PR) is to evaluate&#xD;
      obstetric, neonatal, and infant outcomes among women who required at least one in-hospital or&#xD;
      ambulatory medication for mild to severe COVID-19 at any time during pregnancy or within 90&#xD;
      days prior to the first day of the last menstrual period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale and background: Medicine developers, academic labs, and other organizations&#xD;
      globally are developing medical products to treat COVID-19. Potential treatments include&#xD;
      medications currently used or studied to treat other diseases (&quot;repurposed&quot; treatments), as&#xD;
      well as medications newly identified or designed to treat COVID-19. Pregnant women will be&#xD;
      treated with these medications which, for the most part, lack scientific evidence regarding&#xD;
      safety for the mother and the developing offspring.&#xD;
&#xD;
      Objective: The objective of the COVID-19 International Drug Pregnancy Registry (COVID-PR) is&#xD;
      to estimate the effect that medications indicated for mild to severe COVID-19 have on&#xD;
      obstetric, neonatal, and infant outcomes.&#xD;
&#xD;
      Endpoints: Primary Endpoints: Risk of obstetric outcomes (gestational diabetes, hypertensive&#xD;
      disorders during pregnancy, postpartum hemorrhage, Cesarean section, preterm delivery),&#xD;
      neonatal outcomes (major congenital malformations, low birth weight, small for gestational&#xD;
      age), and infant outcomes until 1 year of age (physical and cognitive developmental&#xD;
      milestones).&#xD;
&#xD;
      Secondary Endpoints: Risk of obstetric outcomes (miscarriage, stillbirth, neonatal death,&#xD;
      maternal death), neonatal outcomes (number of days in NICU), infant outcomes until 1 year of&#xD;
      age (COVID-19, severe infections), and maternal outcomes until the infant's 1 year of age&#xD;
      (e.g., depression, COVID-19 re-infection and other infections).&#xD;
&#xD;
      Study design: The COVID-PR is an international, noninterventional, post-marketing cohort&#xD;
      study designed to collect prospective safety data among pregnant women treated&#xD;
      pharmacologically for mild to severe COVID-19 at any time during pregnancy or within 90 days&#xD;
      prior to the first day of the last menstrual period (LMP). It includes maternal and offspring&#xD;
      follow-up until the infant's one year of age.&#xD;
&#xD;
      Population: The study population includes women 18 years of age and older who required&#xD;
      in-hospital or ambulatory pharmacological treatment for mild to severe COVID-19 at any time&#xD;
      during pregnancy or within 90 days prior to the first day of the LMP. Registration and&#xD;
      participation via website especially developed for the COVID-PR are voluntary. Eligible women&#xD;
      can enroll at any time during pregnancy and up to 30 days after the end of pregnancy.&#xD;
      Postpartum mothers and their live offspring are followed-up to the infant's one year of age.&#xD;
&#xD;
      Exposure: Women are considered exposed if they received at least one dose of a medication&#xD;
      indicated for the treatment of mild to severe COVID-19 at any time during pregnancy or within&#xD;
      90 days prior to the first day of the LMP. The reference groups include pregnant women&#xD;
      treated with another therapy for mild to severe COVID-19 (active comparator) and pregnant&#xD;
      women hospitalized but not treated with a medication specifically indicated for the treatment&#xD;
      of mild to severe COVID-19 (unexposed comparator for hospitalized exposed patients), matched&#xD;
      based on calendar time, country of residence, gestational week of COVID-19 infection (+ / - 2&#xD;
      weeks), and severity of COVID-19.&#xD;
&#xD;
      Data collection: Pregnancy data are collected at enrollment, monthly, and at the end of&#xD;
      pregnancy. Data on mothers and liveborn infants are collected at birth and then every three&#xD;
      months until the infant's 12 months of age. Information is obtained directly from the&#xD;
      participant. Detailed information is collected on COVID-19 symptoms, severity markers, and&#xD;
      treatments. Additionally, a COVID-PR research scientist calls the mother within 90 days after&#xD;
      birth to answer any questions she may have about the registry and to request any missing&#xD;
      information. The COVID-PR collects data on potential confounding factors (such as maternal&#xD;
      sociodemographic characteristics, behaviors, reproductive history, use of assisted&#xD;
      reproductive techniques, pre-pregnancy history of COVID-19 and test results, chronic&#xD;
      conditions, use of medications, and measures of healthcare utilization) and detailed&#xD;
      information associated with the obstetric, neonatal, and infant outcomes. Given the&#xD;
      international nature of the COVID-PR, the questionnaires are available in the languages&#xD;
      spoken where it is conducted. Likewise, the phone call is conducted in the language spoken by&#xD;
      the mother. Participant confidentiality and anonymity are strictly upheld.&#xD;
&#xD;
      Analysis: Exposure to medications indicated for mild to severe COVID-19 during specific&#xD;
      etiologically relevant periods will be considered when estimating the risk for each outcome&#xD;
      (e.g., first trimester for miscarriages and malformations). Relative risks and their 95%&#xD;
      confidence interval (CI) will be presented unadjusted and adjusted using propensity scores&#xD;
      (PS) to account for imbalances in disease severity, comorbidities, and other characteristics&#xD;
      between the exposed and the reference groups.&#xD;
&#xD;
      Study size: Medications indicated for mild to severe COVID-19 will be analyzed separately by&#xD;
      brand. Efforts will be made to collect at least 100 pregnancies treated with specific&#xD;
      medications during the first trimester and at least 100 exposed thereafter during pregnancy.&#xD;
      For each exposed pregnancy, one pregnancy treated with another therapy for mild to severe&#xD;
      COVID-19 (active comparator) and one pregnancy hospitalized but not treated with a medication&#xD;
      specifically indicated for the treatment of mild to severe COVID-19 (unexposed comparator for&#xD;
      hospitalized exposed patients) will be matched based on calendar time, country of residence,&#xD;
      gestational week of COVID-19 infection (+ / - 2 weeks), and severity of COVID-19.&#xD;
&#xD;
      Milestones: The total duration of the study will be 5 years. Obstetric, neonatal, and infant&#xD;
      outcomes will be assessed on an ongoing basis as data become available. The first two years&#xD;
      will include, primarily, enrollment of pregnancies; the third and fourth years will involve&#xD;
      follow-up of pregnancies and newborns; and, the final year, will be for data analyses and&#xD;
      publications. Annual interim reports will be submitted to the Scientific Advisory Committee&#xD;
      (SAC) for their review and feedback as well as abbreviated semiannual progress reports&#xD;
      summarizing cumulative results on key outcomes. A final report will be prepared at the end of&#xD;
      the study.&#xD;
&#xD;
      Governance: The COVID-PR is conducted by Pregistry and includes an internal Safety Management&#xD;
      Team (SMT) of experienced pharmacovigilance professionals and a dysmorphologist that meet&#xD;
      regularly to review individual cases and safety signals. Additionally, the COVID-PR is in&#xD;
      consultation with experts from relevant fields, such as maternal-fetal medicine, infectious&#xD;
      diseases, epidemiology, and biostatistics from academic institutions and private practice.&#xD;
      These individuals constitute the SAC and provide an independent review of the COVID-PR data.&#xD;
&#xD;
      Sponsors: Pharmaceutical companies that hold the marketing authorization of medications for&#xD;
      mild to severe COVID-19 are invited to sponsor the COVID-PR.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Obstetric outcomes</measure>
    <time_frame>1 year</time_frame>
    <description>Number of pregnant women who received at least one dose of a medication indicated for the treatment of mild to severe COVID-19 and number of pregnant women in the reference cohorts who experience gestational diabetes, hypertensive disorders during pregnancy, postpartum hemorrhage, Cesarean section, or preterm delivery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neonatal outcomes</measure>
    <time_frame>1 year</time_frame>
    <description>Number of newborns of women who received at least one dose of a medication indicated for the treatment of mild to severe COVID-19 and number of newborns of pregnant women in the reference cohorts who experience major congenital malformations, low birth weight, or small for gestational age.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infant weight</measure>
    <time_frame>1 year</time_frame>
    <description>Change in weight from birth to 3, 6, 9, and 12 months of age among newborns of women who received at least one dose of a medication indicated for the treatment of mild to severe COVID-19 and among newborns of pregnant women in the reference cohorts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infant developmental milestones</measure>
    <time_frame>1 year</time_frame>
    <description>Change in developmental milestones from baseline at 6, 9, and 12 months based on the tool Caregiver Reported Early Development Instruments among the offspring of women who received at least one dose of a medication indicated for the treatment of mild to severe COVID-19 and among the offspring of pregnant women in the reference cohorts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infant height</measure>
    <time_frame>1 year</time_frame>
    <description>Change in height from birth to 3, 6, 9, and 12 months of age among newborns of women who received at least one dose of a medication indicated for the treatment of mild to severe COVID-19 and among newborns of pregnant women in the reference cohorts.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Obstetric outcomes</measure>
    <time_frame>1 year</time_frame>
    <description>Number of pregnant women who received at least one dose of a medication indicated for the treatment of mild to severe COVID-19 and number of pregnant women in the reference cohorts who experience miscarriage, stillbirth, neonatal death, or maternal death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal outcomes</measure>
    <time_frame>1 year</time_frame>
    <description>Number of recently pregnant women who received at least one dose of a medication indicated for the treatment of mild to severe COVID-19 and number of recently pregnant women in the reference cohorts who experience depression, COVID-19 re-infection and other infections.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Exposed pregnant women</arm_group_label>
    <description>Pregnant women who received at least one dose of a medication indicated for the treatment of mild to severe COVID-19 at any time during pregnancy or within 90 days prior to the first day of the LMP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active comparator pregnant women</arm_group_label>
    <description>Pregnant women treated with another therapy for mild to severe COVID-19</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Unexposed pregnant women</arm_group_label>
    <description>Pregnant women hospitalized but not treated with a medication specifically indicated for the treatment of mild to severe COVID-19</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Monoclonal antibody</intervention_name>
    <description>Medications indicated for the treatment of mild to severe COVID-19</description>
    <arm_group_label>Active comparator pregnant women</arm_group_label>
    <arm_group_label>Exposed pregnant women</arm_group_label>
    <other_name>Remdesivir</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population includes women 18 years of age and older who required in-hospital or&#xD;
        ambulatory pharmacological treatment for mild to severe COVID-19 at any time during&#xD;
        pregnancy or within 90 days prior to the first day of the LMP. Registration and&#xD;
        participation via website especially developed for the COVID-PR are voluntary. Eligible&#xD;
        women can enroll at any time during pregnancy and up to 30 days after the end of pregnancy.&#xD;
        Postpartum mothers and their live offspring are followed-up to the infant's one year of age&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant women or recently pregnant women (up to 30 days after the end of pregnancy)&#xD;
&#xD;
          -  Aged 18 years or older&#xD;
&#xD;
          -  With mild to severe COVID-19 during pregnancy&#xD;
&#xD;
          -  Either&#xD;
&#xD;
               -  Was treated for COVID-19 during hospitalization or ambulatory care with at least&#xD;
                  one medication indicated for mild to severe COVID-19 during pregnancy or within&#xD;
                  90 days prior to the first day of the LMP or&#xD;
&#xD;
               -  Was hospitalized but not treated with any indicated for mild to severe COVID-19&#xD;
&#xD;
          -  Able and willing to sign the electronic informed consent form agreeing to the&#xD;
             conditions and requirements of the COVID-PR&#xD;
&#xD;
          -  Willing to upload the minimum required data of the initial baseline questionnaire&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        ‚óè &lt;18 years of age&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Persons assigned gender female at birth.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diego Wyszynski, MD, MHS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pregistry</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diego Wyszynski, MD, MHS, PhD</last_name>
    <phone>18006163791</phone>
    <email>covid-pr@pregistry.com</email>
  </overall_contact>
  <link>
    <url>https://corona.pregistry.com</url>
    <description>COVID-19 International Drug Pregnancy Registry (COVID-PR)</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 17, 2021</study_first_submitted>
  <study_first_submitted_qc>August 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2021</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remdesivir</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

